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Abstract
Aspergillus fumigalus is a ubiquitous fungus that causes an infection called aspergillosis
in immune-compromised surgery patients (Latge, 2001, 384; Bok et al. 2006). Aspergillosis
cases have increased in the past decade due to the increasing number of patients undergoing
immunosuppressive therapy and receiving organ transplants (Bok et al. 2006). Although there is
still disagreement as to the causative agent of the symptoms accompanying aspergillosis, many
scientists suspect that the compound, gliotoxin, plays a major role, hi this study, we compared
the amounts of gliotoxin produced from clinical and environmental isolates of A. fumigatus. We
hypothesized that the amount of gliotoxin produced would be higher in the clinical isolates in
comparison to the environmental isolates. Cell assay results showed that the clinical isolates
produced more gliotoxin than the environmental isolates while the HPLC results showed no
significant difference between gliotoxin production in clinical and environmental isolates.
Introduction
Aspergillus fumigatus is an opportunistic fungus that causes infections in immune-compromised
surgery patients (Latge, 2001, 384). Aspergillus fumigatus causes an infection called aspergillosis (Bok et
al. 2006). The incidence of Aspergillosis has increased in the past decade because of the increasing
number of patients receiving organ transplants and immunosuppressive therapy (Bok et al. 2006). A.
fumigatus is characterized as having a blue-green to grey colony coloration (doctorfungus). Compounds
produced b\/ A. fumigatus and suspected to be virulence factors are proteases and toxins produced by
the fungi that might interfere with the lung epithelium (Latge, 2001, 384). Other molecules produced
during the growth A. fumigatus that may aid in the mold's survival in the respiratory mucosa of the host
include ribonuclease which causes host cell death, haemolysin which causes red blood cell lysis, and
secondary metabolites such as gliotoxin which causes immunosuppression (Latge, 2001, 384).
Aspergillus fumigatus establishes itself in the tissue of the patient to cause the illness.
The life cycle of Aspergillus fumigatus begins when asexual conidiophores are released into the
environment (Bignell et. al 2004). Vegetative mycelium then give rise to more mycelia in the growing
environment (Bignell et. al 2004). The features of A. fumigatus that increase its rate of infection are the
small size of conidia, the large number of conidia produced from a single spore event, and the ability of
the conidia to grow in different temperatures (Latge 2001). Also, there are no specific nutrient
requirements for the growth of the mycelia (Latge 2001, 384). Therefore, there are various factors
aiding in the survival of Aspergillus fumigatus.
To cause invasive aspergillosis, the conidia migrate to the alveoli and spread mycelia (Amitani et
al. 1995). Amitani et al. (1995) found that clinical isolates of A. fumigatus slow ciliary beat frequency
(CBF) by producing factors that damage cilia in vivo. Different body parts have different chances of
infection and rates of cure and survival once infection has occurred (Singh 2005). Some parts of the
body show A. fumigatus infections late in the surgical recovery period while others have it early.
Invasive aspergillosis mostly affects transplant recipients (Singh 2005).
In the lungs, A. fumigatus works by attacking the respiratory mucosa to cause complications due
to production of toxic molecules. This type of infection is referred to as bronchopulmonary aspergillosis
(Amitani et al. 1995). Singh (2005) found that single lung transplant patients were more likely to develop
invasive aspergillosis if they had chronic obstructive pulmonary disease. The higher likelihood of
aspergillosis might be because the spores are retained longer in the lung tissue, thus giving them time to
establish their mycelia (Singh 2005). Also, invasive aspergillosis in single lung transplant recipients occurs
later in the recovery period, and there is an increased likelihood of invasive aspergillosis compared to
tracheobronchitis patients (Singh 2005). The mortality rate of single lung transplant patients is also
higher than that of other lung transplant recipients (Singh 2005). Overall, the virulence factors are many
but one that has received significant attention in the past decades is gliotoxin.
Gliotoxin is among a group of secondary metabolites that are suspected of causing
immunosuppression. This group also includes fumagatin, fumagillin, helvoic acid, etc (Bok et al. 2006).
Gliotoxin has been shown to have immunosuppressive effects by slowing the ciliary beat frequency
(Amitani et al., 1995). Gliotoxin is immunosuppressive at relatively low concentrations of 0.03-lug/ml.
Gliotoxin first gained attention for its antibiotic qualities (Kaufmann et al. 2000). Despite its
antimicrobial activity against fungus and bacteria, its immunosuppressive effects have prevented its
clinical use (Tuch et al. 1988). Gliotoxin belongs to a group of compounds called
epipolythiodioxopiperazines (Tuch et al. 1988). The reactive sulfur component of gliotoxin is thought to
be responsible for its toxicity (Sutton et al. 1996). Gliotoxin inhibits phagocytosis, T-cell proliferation,
cytolytic T lymphocytes activation, and adherence of macrophage, blood monocytes, fibroblasts and
L929 cells (Kaufmann et al. 2000). Gliotoxin acts by inactivating antigen-presenting cells and facilitating
genomic destruction of such cells (Tuch et al. 1988). Gliotoxin may also cause immunosuppression
through production of reactive oxygen species, inhibition of NF-/cB and by inducing DNA damage
through substrate cycling (Kaufmann et al. 2000).
In this study compared the amount of gliotoxin produced from with clinical and environmental
isolates of A. fumigatus. We assumed that more gliotoxin production means that the strain is more
virulent and likely to cause more sickness in the immune-compromised patient. We hypothesized that
there will be more gliotoxin production in clinical isolates of A. fumigatus than in environmental strains
of A. fumigatus.
Materials and Methods
Part 1. High Performance Liquid Chromatography
Chloroform extraction
The first step in extracting gliotoxin from Aspergillus fumigatus is culturing>Asperg/7/us
fumigatus on five Sabouraud agar plates for 2 days at 37 C. Secondly, we harvested the conidia using
sterile 0.5% Tween 20. Then we adjusted the concentration of conidia 10''mr^ in distilled water using a
hemocytometer. Thirdly, we used 1ml of this conidial suspension to inoculate 100ml of Czapek-dox
broth in a 250ml flask. Afterwards, we incubated cultures at 37 C in a shaking incubator at 1400 rpm for
2 days. Then, we harvested fungal biomass by filtration through Whatman N°l filter paper in a Buchner
funnel. We extracted the filtrate three times by shaking for 10 min with 50 ml chloroform at 25 C. We
evaporated the extracts in the tubes to dryness by immersing in a water bath. We added 10 ml
methanol in each of the tubes and store at -70°C until use.
Preparing the extracts for HPLC included diluting the gliotoxin extract 1/50 in 50% methanol
50% deionized-distilled water (the mobile phase) and injecting lO^il into the HPLC. Construct a standard
curve of peak height versus gliotoxin by injection of 20|il of gliotoxin standards (50, 100 and 200ngmr^
dissolved in the mobile phase) into the HPLC. To make the standard curve, we purchased synthetic
gliotoxin and detected the lowest level at which gliotoxin could still be detected. We did this by diluting
the gliotoxin and observing the absorbance (based on method by Richard ef al. 1989). We performed
five dilutions of synthetic gliotoxin (lOOug/ml, lOug/ml, lug/ml, 0. lug/ml, O.Olug/ml) in 70% methanol
and ran them on an HPLC machine to determine the lowest amount that could still be detected. We
made a graph of the area under the peak versus the concentration of the toxin. The procedure for HPLC
analysis was adapted from a study by Richard et al. (1989). We used the equation from the calibration
curve to find the amount of gliotoxin injected. The isolates were numbered but their identity was hidden
to prevent a biased interpretation of the results.
Table 1. Dilutions of Gliotoxin
Concentration (ug/ml) Injected (1ml into HPLC)
1000 10 ug
1:10 100 lug
1:20 50 0.5 ug
1:25 40 0.4 ug
1:50 20 0.2 ug
Part 2. Cell Assav
The L929 cells (mouse lung fibroblast cells) have previously been found to be detached from
well plate by gliotoxin. We Cultured mouse lung fibroblast cells (L929) in Dulbecco's modified eagle's
medium (DMEM) containing 10% fetal calf serum (PCS) at 37°C for 2 days. We incubated the plates in 5%
CO2 for 2h at 37 C. We made a suspension of L929 cells that were now labeled with methyl dye. The cells
were added to a 96 well plate. We incubated the cells for two hours.
After two hours we discarded the culture medium and washed the cell monolayers by adding
excess PBS pH 7.3 at room temperature to the wells of the microtitre plate. We added culture extract to
the cells. Some cells were detached from the plate while other remained attached. We removed the
cells that were detached. Detergent Triton X-100 was used to lyse cells that remained attached to the
plates. When cells lyse they will release neutral red which can be analyzed for amount using a
spectrophotometer. The positive control was gliotoxin of different amounts.
Results
In general, there was a weak trend showing higher absorbance for the clinical isolates. HPLC
results and calculations of the amount of gliotoxin in the samples in micrograms using standard curve
equation are as follows:
Table 2, Amount of gliotoxin in cell extract by chloroform
Sample Area ug in Culture Tube
5215 9787 0.32559
5216 37064 3.05329
5267 184
5854 68887 6.23559
5211 4018
5262
5217
5263
5214
Table 3. Gliotoxin standardization curve
Dilution Injected (ug) Area of Peak
10 7567317
1 1052354
0.5 554641
0.4 371297
0.2 246826
Figure 1. Gliotoxin Calibration Curve
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We used Whitney Mann non-parametric test to check the significance between peak areas of
clinical and environmental isolates. Non-parametric tests use rankings instead of numbers. Unlike
parametric tests such as ANOVA, they do not assume a normal distribution. Results showed that the
amount of gliotoxin produced by the clinical and environmental isolates was not significantly different
{W=22.5,P= 0.556).
Ranks
Sarrple N Mean Rank Sum of Ranks
Area 1
2
Total
5
4
9
4.50
5.63
22.50
22.50
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Discussion
Using standard dilutions of synthetic gliotoxin, we consistently found a peak at eleven
nninutes for the five dilutions. When making the standard curve one dilution was omitted because it was
an outlier. The eleven minute peak has previously been found to indicate the presence of gliotoxin.
None of the samples, whether clinical or environmental, produced peaks areas close to the area of the
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lowest dilution of synthetic gliotoxin, 0.2ug. This was chosen as the lowest dilution because gliotoxin
shows toxic effects at concentrations as low as 0.03-lug/iTil. All the calculated values for the amount of
gliotoxin in the samples were less that 0.2ug. The clinical isolates were labeled 5211, 5214, 5262, 5263,
and 5854. The environmental isolates were 5215, 5216, 5217, and 5267. Three of the environmental
isolates produced a peak while two of the clinical isolates produced a peak (Table 2). The standard curve
equation was used to estimate the amount of gliotoxin in each extract. Most of the calculated values for
the amount of gliotoxin in the samples showed that the amount of gliotoxin was very low or absent.
Scientists could extend this study by having a higher number of samples for the trials.
More samples could be used to note trends within the clinical and environmental isolates. Since a
majority of the samples did not produce a peak for the gliotoxin, maybe a more sensitive method should
be used. Gliotoxin may be the virulence factor but results from this study do not adequately support our
hypothesis that the amounts of gliotoxin would be higher in the clinical isolates of A. fumigatus. It might
be that gliotoxin is a major virulence factor when combined with the other compounds released during
growth of the mold. The effects of other compounds such as ribonuclease and haemolysin might
combine with the effects of gliotoxin to produce the serious symptoms of aspergillosis.
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